Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Alabama: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- The Kirklin Clinic at Acton Road — Birmingham, Alabama
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
- Thomas Hospital — Fairhope, Alabama
- Mobile Infirmary Medical Center — Mobile, Alabama
Phase 3 Recruiting Industry
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …
Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Alabama: - Clearview Cancer Institute — Huntsville, Alabama
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Alabama: - Clearview Cancer Institute — Huntsville, Alabama
- Infirmary Cancer Care — Mobile, Alabama
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in Alabama: - Local Institution - 0347 — Birmingham, Alabama
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Alabama: - Local Institution - 0487 — Mobile, Alabama
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06031688
Sites in Alabama: - Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
- Thomas Hospital — Fairhope, Alabama
- Mobile Infirmary Medical Center — Mobile, Alabama
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland — Saraland, Alabama
Phase 2 Recruiting Industry
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in Alabama: - Southern Cancer Center, PC — Daphne, Alabama
- Clearview Cancer Institute — Huntsville, Alabama
Phase 2 Recruiting Industry
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06095505
Sites in Alabama: - Southern Cancer Center — Daphne, Alabama
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutat…
Sponsor: Taiho Oncology, Inc.
NCT ID: NCT05967689
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Industry
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-del…
Sponsor: Bayer
NCT ID: NCT06914128
Sites in Alabama: - UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
Phase 2 Recruiting Industry
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this stud…
Sponsor: Boehringer Ingelheim
NCT ID: NCT05882058
Sites in Alabama: - Infirmary Cancer Care — Mobile, Alabama
Phase 2 Recruiting Industry
The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06788912
Sites in Alabama: - Southern Cancer Center (SCC) ( Site 8004) — Daphne, Alabama
Phase 1, Phase 2 Recruiting Industry
The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in patients with ovarian cancer and Non Sm…
Sponsor: Tubulis GmbH
NCT ID: NCT06303505
Sites in Alabama: - The University of Alabama — Birmingham, Alabama
Phase 2 Recruiting Industry
This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemotherapy (ICT: Pembrolizumab, Pemetrexed,…
Sponsor: CatalYm GmbH
NCT ID: NCT07098988
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 2 Recruiting Industry
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , N…
Sponsor: Advenchen Pharmaceuticals, LLC.
NCT ID: NCT05363280
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Industry
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and u…
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT ID: NCT06343402
Sites in Alabama: - O'Neal Comprehensive Cancer Center at UAB — Birmingham, Alabama
Phase 1 Recruiting Industry
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT06293898
Sites in Alabama: - University of Alabama Birmingham — Birmingham, Alabama
Phase 1 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or met…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06562192
Sites in Alabama: - Uni of Alabama at Birmingham — Birmingham, Alabama
Recruiting Academic/Other
The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor (EGFR)-mutant Non-Sm…
Sponsor: PrECOG, LLC.
NCT ID: NCT06538038
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Recruiting Industry
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and di…
Sponsor: Tempus AI
NCT ID: NCT05236114
Sites in Alabama: - Alabama Oncology — Birmingham, Alabama